The remaining ten drugged proteins were targeted by compounds indicated for treatment of cancers (CAN2, EPHB1, ERAP1, GSTM3, NQO1, and PVRL4), mitochondrial and muscular disease (NQO1), and metabolic syndrome (CEL; Table S10). This evidence concerns the gene NQO1 and metabolic syndrome.